Tumor and autoimmune disease seriously endanger human health. Our primary mission is to develop novel and highly-effective drugs to satisfy the unmet medical needs of patients.
Based on our in-depth understanding of disease mechanisms, we have established protein homeostasis technology platform and Degrader Antibody Conjugate（DAC） platform, targeting proteins highly related to the occurrence and development of diseases, and eventually accelerate the discovery of innovative drug molecules.
As a high-tech pharmaceutical company with originally innovative capability, we are dedicated to develop novel drugs against undruggable targets through taking advantage of Molecular Glue and Protac technology, which in turn provides effective solutions for original innovative drugs.
The DAC (Degrader Antibody Conjugate) technology platform is our core next-generation targeted therapy technology. It innovatively couples highly specific antibodies with catalytic protein degraders (such as molecular glues), combining the dual advantages of both: achieving targeted delivery to tissues and cells through the "precise navigation" of antibodies, and then utilizing the intracellular "catalytic degradation" mechanism of degraders to directly eliminate pathogenic target proteins.This approach breaks through the limitations of traditional "undruggable" targets, achieving a therapeutic leap from inhibition to clearance and improving safety.
| Program | Modality | Indication | Discovery | Preclinical | Early phase development | Late phase development |
| HP-001 | Molecular glue | Hematologic Malignancies |
|
|||
| HP-002 | Protac | Hematologic Malignancies |
|
|||
| HP-003 | Molecular glue | Autoimmune |
|
|||
| CY002 | Molecular glue | Solid tumor |
|
|||
| CY006 | DAC | Tumor/Autoimmune |
|
|||
| CY008 | Protac | Autoimmune |
|
|||
